The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis

The Childhood Arthritis Prospective Study (CAPS) is funded by Versus Arthritis (UK grant no. 20542). JEMcD and KLH are supported by Versus Arthritis Centre for Epidemiology (UK grant no. 21755) and by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). SJWSW is supported by the Medical Research Council (MR/ R013926/1), Versus Arthritis (UK grant number 22084), Great Ormond Street Hospital Children's Charity (VS0518), and Olivia's Vision through the CLUSTER consortium. This report includes independent research funded by the NIHR BRC Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work formed part of an Applied Personal Excellence Pathway project for the MB ChB degree, through the Faculty of Biology, Medicine and Health at the University of Manchester. S.J.W. Shoop-Worrall, PhD, MSc, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, and Centre for Health Informatics, The University of Manchester; L. Moull, MBChB, School of Medical Sciences, The University of Manchester; J.E. McDonagh, MD, FRCP, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester; K.L Hyrich, Professor, MD, PhD, FRCPC, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, and NIHR Manchester BRC, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. S.J.W. Shoop-Worrall and L. Moull are joint first authors. JEMcD has received advisory board membership fees from Pfizer and CSL-Behring. KLH has received honoraria from AbbVie, and grant support from Pfizer and BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.J.W. Shoop-Worrall, Centre for Epidemiology Versus Arthritis, 2.908 Stopford Building, Manchester, M13 9PT, UK. Email: stephanie.shoop-worrall@manchester.ac.uk. Accepted for publication March 9, 2022.

The Childhood Arthritis Prospective Study (CAPS) is funded by Versus Arthritis (UK grant no. 20542). JEMcD and KLH are supported by Versus Arthritis Centre for Epidemiology (UK grant no. 21755) and by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). SJWSW is supported by the Medical Research Council (MR/ R013926/1), Versus Arthritis (UK grant number 22084), Great Ormond Street Hospital Children's Charity (VS0518), and Olivia's Vision through the CLUSTER consortium. This report includes independent research funded by the NIHR BRC Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work formed part of an Applied Personal Excellence Pathway project for the MB ChB degree, through the Faculty of Biology, Medicine and Health at the University of Manchester. S.J.W. Shoop-Worrall, PhD, MSc, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, and Centre for Health Informatics, The University of Manchester; L. Moull, MBChB, School of Medical Sciences, The University of Manchester; J.E. McDonagh, MD, FRCP, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester; K.L Hyrich, Professor, MD, PhD, FRCPC, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, and NIHR Manchester BRC, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. S.J.W. Shoop-Worrall and L. Moull are joint first authors. JEMcD has received advisory board membership fees from Pfizer and CSL-Behring. KLH has received honoraria from AbbVie, and grant support from Pfizer and BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.J.W. Shoop-Worrall, Centre for Epidemiology Versus Arthritis, 2.908 Stopford Building, Manchester, M13 9PT, UK. Email: stephanie.shoop-worrall@manchester.ac.uk. Accepted for publication March 9, 2022.

The Childhood Arthritis Prospective Study (CAPS) is funded by Versus Arthritis (UK grant no. 20542). JEMcD and KLH are supported by Versus Arthritis Centre for Epidemiology (UK grant no. 21755) and by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). SJWSW is supported by the Medical Research Council (MR/ R013926/1), Versus Arthritis (UK grant number 22084), Great Ormond Street Hospital Children's Charity (VS0518), and Olivia's Vision through the CLUSTER consortium. This report includes independent research funded by the NIHR BRC Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work formed part of an Applied Personal Excellence Pathway project for the MB ChB degree, through the Faculty of Biology, Medicine and Health at the University of Manchester. S.J.W. Shoop-Worrall, PhD, MSc, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, and Centre for Health Informatics, The University of Manchester; L. Moull, MBChB, School of Medical Sciences, The University of Manchester; J.E. McDonagh, MD, FRCP, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester; K.L Hyrich, Professor, MD, PhD, FRCPC, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, and NIHR Manchester BRC, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. S.J.W. Shoop-Worrall and L. Moull are joint first authors. JEMcD has received advisory board membership fees from Pfizer and CSL-Behring. KLH has received honoraria from AbbVie, and grant support from Pfizer and BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.J.W. Shoop-Worrall, Centre for Epidemiology Versus Arthritis, 2.908 Stopford Building, Manchester, M13 9PT, UK. Email: stephanie.shoop-worrall@manchester.ac.uk. Accepted for publication March 9, 2022.

The Childhood Arthritis Prospective Study (CAPS) is funded by Versus Arthritis (UK grant no. 20542). JEMcD and KLH are supported by Versus Arthritis Centre for Epidemiology (UK grant no. 21755) and by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). SJWSW is supported by the Medical Research Council (MR/ R013926/1), Versus Arthritis (UK grant number 22084), Great Ormond Street Hospital Children's Charity (VS0518), and Olivia's Vision through the CLUSTER consortium. This report includes independent research funded by the NIHR BRC Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work formed part of an Applied Personal Excellence Pathway project for the MB ChB degree, through the Faculty of Biology, Medicine and Health at the University of Manchester. S.J.W. Shoop-Worrall, PhD, MSc, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, and Centre for Health Informatics, The University of Manchester; L. Moull, MBChB, School of Medical Sciences, The University of Manchester; J.E. McDonagh, MD, FRCP, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester; K.L Hyrich, Professor, MD, PhD, FRCPC, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, and NIHR Manchester BRC, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. S.J.W. Shoop-Worrall and L. Moull are joint first authors. JEMcD has received advisory board membership fees from Pfizer and CSL-Behring. KLH has received honoraria from AbbVie, and grant support from Pfizer and BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.J.W. Shoop-Worrall, Centre for Epidemiology Versus Arthritis, 2.908 Stopford Building, Manchester, M13 9PT, UK. Email: stephanie.shoop-worrall@manchester.ac.uk. Accepted for publication March 9, 2022.